The field of bispecific antibodies is advancing rapidly with results demonstrating their effective use in immunotherapy and oncology, as well as applications that are emerging in ophthalmology, infectious disease, and inflammation. This conference will highlight novel engineering approaches to bispecific antibody constructs and reveal key elements for efficacy and drug-like properties. The latest improvements in manufacturing, purification, stability, enhanced targeting, modulating immune response, expression, characterization, humanization and clearance will be shared.
Enhancing Function CrossMAb Vh-Vl and Fab
Jörg T. Regula, Ph.D., Head, Protein Analytics, Roche Diagnostics GmbH Roche
Multimerization Strategy to Enhance Potency and Developability of Bispecific Antibodies
Mahiuddin Ahmed, Ph.D., Assistant Attending for Immunotherapies, Pediatrics, Memorial Sloan Kettering Cancer Center
Bispecific FynomAbs with Tailored Architecture and Novel Modes-of-Action
Simon Brack, Ph.D., Director, Discovery Research, Discovery Research, Covagen (one of the Janssen pharmaceutical companies of Johnson & Johnson)
How to Minimalize Antibodies: The Success of Antibodies as Pharmaceuticals Has Triggered Interest in Crafting Much Smaller Mimics
Patrick J. McEnaney, Ph.D., Postdoctoral Researcher, Departments of Cancer Biology and Chemistry, The Scripps Research Institute Florida
Engineering Next-Generation Biotherapeutics: Developability & Manufacturability
Maria Wendt, Ph.D., Head, Science, Genedata
Arming of Effector T Cells or Tregs with BiTEs or CARs
Michael P. Bachmann, Ph.D., Professor, Helmholtz Zentrum Dresden Rossendorf (HZDR); Institute of Radiopharmaceutical Cancer Research, Radio-/Tumorimmunology
Developing Full-Length CD3 Bispecific Antibodies: From Bench to NHP
Javier Chaparro-Riggers, Ph.D., Director, Antibody Technology, Rinat Pfizer, Inc.
(scFab)2-Fc Type Bispecific Antibodies Engaging T Cells for Cancer Immunotherapy
Hyung-Kwon (Harry) Lim, Ph.D., Senior Research Scientist, Antibody Engineering, MOGAM Biotechnology Institute
A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing Lymphoma Cells
Jie Liu, M.D., Ph.D., Senior Scientist, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
Title to be Announced
Hari Hariharan, Ph.D., Senior Director, Biotherapeutics Drug Discovery & Tech Development, Celgene Corp.
A Tale of Two Bacteria…Developing Bispecific Antibody Drugs for Pseudomonas aeruginosa and Clostridium difficile
G. Jonah Rainey, Ph.D., Senior Scientist, ADPE, MedImmune, LLC
Bispecific Antibodies Perform a Disappearing Act
Katherine Cygnar, Ph.D., Staff Scientist, Genome Engineering Technologies, Regeneron Pharmaceuticals, Inc.
Bispecific Antibody for Non-Oncology Disease Area Focusing on Hemophilia, a Bispecific Antibody
Shinya Ishii, Ph.D., Research Scientist, Discovery Research Dept, Chugai Pharmaceutical Co., Ltd.
For more details on the conference, please contact:
For partnering and sponsorship information, please contact:
Executive Director, Conferences
Manager, Business Development
Cambridge Healthtech Institute
Director, Business Development
Cambridge Healthtech Institute